Last checked at 20 Feb 2020 07:00
20 February 2020
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Oxford BioDynamics to present at BioTech Pharma Summit: Liquid Biopsy 2020 in Lisbon, Portugal
·; Results from non-invasive blood-based EpiSwitch™ biomarker studies demonstrate the relevance of the 3D Genomics biomarker modality to clinical outcomes in patients, across multiple applications.
·; Blood-based stratifications of patients for diagnostic, predictive and prognostic applications in neurodegeneration, inflammation and immuno-oncology discussed and directly compared to current gold standards.
·; The rise of innovative technologies in molecular biomarkers offers the possibility of developing new gold standards for personalized medicine.
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that data yielded by the application of its 3D genome architecture technology platform, EpiSwitch™, will be presented at the BioTech Pharma Summit: Liquid Biopsy 2020 held in Lisbon, Portugal on February 20-21, 2020. The summit brings together leaders in the field from pharma, biotech, and diagnostic companies and healthcare providers, fostering collaboration between stakeholders in liquid biopsy, molecular pathology and precision medicine. The expanding field of circulating biomarkers of various classes is redefining the gold standards of personalised healthcare testing.
OBD's presentation "3D Genome Architecture as Biomarker Modality" sets out the advantages of its EpiSwitch™ biomarker platform, the relevance of its biomarkers to clinical outcomes and the systemic nature of its biomarker signatures, as detected non-invasively in peripheral blood.
The presentation will focus on examples of diagnostic, prognostic and predictive stratifications in patients, including in the following disease areas and indications:
- Neurodegeneration - prognostic biomarkers for ALS;
- Inflammation - predictive biomarkers for Rheumatoid Arthritis;
- Oncology - prognostic biomarkers for DLBCL;
- Oncology - predictive biomarkers for PD-1/PD-L1 immuno-checkpoint inhibitors.
Alexandre Akoulitchev, Director and Chief Scientific Officer of Oxford BioDynamics, commented, "We are building an impressive body of evidence for the direct relevance to clinical outcomes of the non-invasive blood-based biomarker readouts generated by our EpiSwitch™ platform. The quality of the classification results delivered - from rheumatoid arthritis and neurodegeneration to immuno-oncology - is a reflection of the fundamental biological nature of regulatory 3D genome architecture and the robustness of the automated, high resolution EpiSwitch™ technology used to monitor it. We are inspired by the full potential of our platform and its role in the future development of precision medicine. "
For further details please contact:
Oxford BioDynamics Plc Christian Hoyer Millar, CEO Alexandre Akoulitchev, CSO Paul Stockdale, CFO
| +44 (0)1865 518910 |
FTI Consulting Financial Public Relations Adviser Natalie Garland-Collins
| +44 (0)20 3727 1000 |
About EpiSwitch™
EpiSwitch™ is a novel epigenetic-based technology platform that supports precision medicine initiatives including: prediction of response to therapy, patient prognosis, disease diagnosis & subtyping and residual disease monitoring. The result of robust, validated, award-winning technology and methodology, EpiSwitch™ stratifies patients based on their genomic architecture to reduce the risk, cost and time to market for therapeutic development programmes, provide significant insights into disease mechanisms and help personalize therapeutics to ensure better outcomes. To learn more about EpiSwitch™, please visit https://www.oxfordbiodynamics.com/technology/.
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
The Company is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.